Ishikawa

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Prostate cancer3 trials
• Coronary artery disease2 trials
• Stroke2 trials
• Systemic sclerosis (scleroderma)2 trials
• Acute lymphoblastic leukaemia1 trial
• ANCA-associated vasculitis1 trial
• Childhood cancers1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Diffuse large B-cell lymphoma1 trial
• Familial hypercholesterolaemia1 trial
• Lupus (SLE)1 trial

Phase

• Phase 26 trials
• Phase 36 trials
• Phase 2/31 trial

Status

• Active, not recruiting9 trials
• Completed3 trials
• Recruiting3 trials

Lead sponsor

• Novartis Pharmaceuticals15 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

  NCT06868290· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06655896· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Specified Drug-use Surveillance of Fabhalta Capsules

  NCT06606314· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

  NCT06581198· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Specified Drug-use Survey of Leqvio for s.c. Injection.

  NCT06275724· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT04747613· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Out of Specification for Tisagenlecleucel

  NCT04094311· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting

Closed trials

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

  NCT05114746· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

  NCT04717635· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source